CSTL (STOCKS)
Castle Biosciences, Inc. Common Stock
$23.530000
+0.400000 (+1.73%)
Prev close: $23.130000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Derek J. Maetzold
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $698.98M
- Employees
- 823
- P/E (TTM)
- -27.78
- P/B (TTM)
- 1.46
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.08 | $-0.29 | +0.2120 | +72.60% |
|
Sep 2025 (Q3)
|
$-0.02 | $-0.53 | +0.5129 | +96.25% |
|
Jun 2025 (Q2)
|
$0.15 | $-0.53 | +0.6838 | +128.10% |
|
Mar 2025 (Q1)
|
$-0.20 | $-0.07 | -0.1275 | -175.86% |
Financial Statements
| Revenues | $344.23M |
| Benefits Costs and Expenses | $0.00 |
| Cost Of Revenue | $71.03M |
| Costs And Expenses | $387.04M |
| Gross Profit | $273.20M |
| Operating Expenses | $316.01M |
| Selling, General, and Administrative Expenses | $229.32M |
| Research and Development | $51.85M |
| Other Operating Expenses | $34.84M |
| Operating Income/Loss | -$42.81M |
| Income/Loss From Continuing Operations After Tax | -$24.16M |
| Income/Loss From Continuing Operations Before Tax | $344.23M |
| Income Tax Expense/Benefit | -$5.36M |
| Income Tax Expense/Benefit, Current | $872.00K |
| Income Tax Expense/Benefit, Deferred | -$6.23M |
| Net Income/Loss | -$24.16M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$24.16M |
| Net Income/Loss Available To Common Stockholders, Basic | -$24.16M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.83 |
| Diluted Earnings Per Share | -$0.83 |
| Basic Average Shares | 28,986,000 |
| Diluted Average Shares | 28,986,000 |
| Common Stock Dividends | $0.00 |
| Assets | $578.56M |
| Current Assets | $361.10M |
| Inventory | $10.25M |
| Other Current Assets | $350.84M |
| Noncurrent Assets | $217.46M |
| Liabilities | $107.68M |
| Current Liabilities | $68.68M |
| Accounts Payable | $18.71M |
| Wages | $38.29M |
| Other Current Liabilities | $11.68M |
| Noncurrent Liabilities | $39.01M |
| Long-term Debt | $10.06M |
| Other Non-current Liabilities | $28.95M |
| Equity | $470.87M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $470.87M |
| Liabilities And Equity | $578.56M |
| Net Cash Flow From Operating Activities | $64.35M |
| Net Cash Flow From Operating Activities, Continuing | $64.35M |
| Net Cash Flow From Investing Activities | -$60.37M |
| Net Cash Flow From Investing Activities, Continuing | -$60.37M |
| Net Cash Flow From Financing Activities | -$6.96M |
| Net Cash Flow From Financing Activities, Continuing | -$6.96M |
| Net Cash Flow | -$2.98M |
| Net Cash Flow, Continuing | -$2.98M |
| Comprehensive Income/Loss | -$24.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$24.12M |
| Other Comprehensive Income/Loss | -$24.12M |